Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial.
acute myeloid leukaemia
daunorubicin
modelling
pharmacokinetics
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
05 Apr 2022
05 Apr 2022
Historique:
received:
08
03
2022
revised:
31
03
2022
accepted:
01
04
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
Daunorubicin pharmacokinetics (PK) are characterised by an important inter-individual variability, which raises questions about the optimal dose regimen in patients with acute myeloid leukaemia. The aim of the study is to assess the joint daunorubicin/daunorubicinol PK profile and to define an optimal population PK study design. Fourteen patients were enrolled in the PK ancillary study of the BIG-1 trial and 6-8 samples were taken up to 24 h after administration of the first dose of daunorubicin (90 mg/m
Identifiants
pubmed: 35456626
pii: pharmaceutics14040792
doi: 10.3390/pharmaceutics14040792
pmc: PMC9029035
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Centre Hospitalier Universitaire d'Angers
ID : AOI2016
Références
Pediatr Blood Cancer. 2010 Mar;54(3):355-60
pubmed: 19731319
Cancer Chemother Rep. 1973 Nov-Dec;57(4):485-8
pubmed: 4586956
Cancer Chemother Pharmacol. 2016 Nov;78(5):1051-1058
pubmed: 27738808
J Pharmacokinet Pharmacodyn. 2001 Oct;28(5):481-504
pubmed: 11768292
Br J Clin Pharmacol. 2011 Apr;71(4):514-21
pubmed: 21204910
Br J Clin Pharmacol. 2003 Oct;56(4):370-7
pubmed: 12968981
Cancer Chemother Pharmacol. 2004 Jul;54(1):39-48
pubmed: 15045528
Blood. 2016 Jan 7;127(1):53-61
pubmed: 26660429
Curr Treat Options Oncol. 2017 Jan;18(1):3
pubmed: 28154969
Cancer Chemother Pharmacol. 2012 May;69(5):1155-63
pubmed: 22212298
Eur J Drug Metab Pharmacokinet. 1991 Apr-Jun;16(2):119-27
pubmed: 1936071
Cancer Chemother Pharmacol. 2014 Oct;74(4):831-8
pubmed: 25119182
Comput Methods Programs Biomed. 2010 Apr;98(1):55-65
pubmed: 19892427
J Pharm Biomed Anal. 2020 Nov 30;191:113576
pubmed: 32889347
Eur J Clin Pharmacol. 2012 Dec;68(12):1577-86
pubmed: 22562609
Curr Drug Metab. 2015;16(6):412-26
pubmed: 26321196